In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 3, 2013, Pages 343-346

  Clock, Sarah A ^a   Tabibi, Setareh ^a   Alba, Luis ^a   Kubin, Christine J ^b   Whittier, Susan ^a   Saiman, Lisa ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Acinetobacter; Doripenem; Drug resistant; Gram negative bacilli; Klebsiella; Susceptibility; Synergy

Indexed keywords

AMIKACIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HOSPITAL INFECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIKACIN; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; RIFAMPIN;

EID: 84879172962     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.03.014     Document Type: Article

References (34)

1. Adler A., Carmeli Y. Dissemination of the Klebsiella pneumoniae carbapenemase in the health care settings: tracking the trails of an elusive offender. mBio 2011, 2:e00280-e00311.
2. Bergen P.J., Tsuji B.T., Bulitta J.B., Forrest A., Jacob J., Sidjabat H.E., et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011, 55:5685-5695.
3. Betriu C., Gomez M., Lopez-Fabal F., Culebras E., Rodriguez-Avial I., Picazo J.J. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur J Clin Microbiol Infect Dis 2010, 29:1179-1181.
4. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., Ambrose P.G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005, 49:3944-3947.
5. Bhusal Y., Shiohira C.M., Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 2005, 26:292-297.
6. Birgy A., Bidet P., Genel N., Doit C., Decre D., Arlet G., et al. Phenotypic screening of carbapenemases and associated beta-lactamases in carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2012, 50:1295-1302.
7. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 21st informational supplement (M100-S21) 2011, CLSI, Wayne, PA.
8. Deshpande L.M., Jones R.N., Fritsche T.R., Sader H.S. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006, 12:223-230.
9. Frei C.R., Wiederhold N.P., Burgess D.S. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008, 61:621-628.
10. Giamarellou H., Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009, 69:1879-1901.
11. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
12. Ikawa K., Morikawa N., Uehara S., Monden K., Yamada Y., Honda N., et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009, 33:276-279.
13. Jernigan M.G., Press E.G., Nguyen M.H., Clancy C.J., Shields R.K. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012, 56:3395-3398.
14. Jones R.N., Sader H.S., Fritsche T.R. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005, 52:71-74.
15. Kuti J.L., Dowzicky M., Nicolau D.P. A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. J Chemother 2008, 20:69-76.
16. Lat A., Clock S.A., Wu F., Whittier S., Della-Latta P., Fauntleroy K., et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 2011, 49:1795-1798.
17. Livermore D.M. Doripenem: antimicrobial profile and clinical potential. Diagn Microbiol Infect Dis 2009, 63:455-458.
18. Livne L., Epand R.F., Papahadjopoulos-Sternberg B., Epand R.M., Mor A. OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J 2010, 24:5092-5101.
19. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
20. Manchanda V., Sanchaita S., Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis 2010, 2:291-304.
21. Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin Infect Dis 2009, 49(Suppl 1):S1-S3.
22. Mera R.M., Miller L.A., Amrine-Madsen H., Sahm D.F. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010, 16:209-215.
23. Miyasaki Y., Morgan M.A., Chan R.C., Nichols W.S., Hujer K.M., Bonomo R.A., et al. In vitro activity of antibiotic combinations against multidrug-resistant strains of Acinetobacter baumannii and the effects of their antibiotic resistance determinants. FEMS Microbiol Lett 2012, 328:26-31.
24. Mushtaq S., Ge Y., Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother 2004, 48:1313-1319.
25. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003, 52:1.
26. Ortho-McNeil-Janssen Pharmaceuticals, Inc Doribax (doripenem for injection) package insert Available at, Accessed November 1, 2012. http://doribax.com/shared/pi/doribax.pdf.
27. Pea F., Pavan F., Nascimben E., Benetton C., Scotton P.G., Vaglia A., et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 2003, 47:3104-3108.
28. Queenan A.M., Shang W., Flamm R., Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 2010, 54:565-569.
29. Rahal J.J. The role of carbapenems in initial therapy for serious Gram-negative infections. Crit Care 2008, 12(Suppl 4):S5.
30. Shields R.K., Kwak E.J., Potoski B.A., Doi Y., Adams-Haduch J.M., Silviera F.P., et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2011, 70:246-252.
31. Souli M., Galani I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13. pii:19045.
32. Srinivasan A., Patel J.B. Klebsiella pneumoniae carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008, 29:1107-1109.
33. Urban C., Mariano N., Rahal J.J. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010, 54:2732-2734.
34. Weisenberg S.A., Schuetz A.N., Alexander E.L., Eiss B., Behta M., Saiman L., et al. Endemic Acinetobacter baumannii in a New York Hospital. PLoS One 2011, 6:e28566.